title: Healthcare-associated infections, infection control and the potential of new antibiotics in development in the USA.
abstract: ABSTRACT  Healthcare-associated infections (HAIs) caused by drug-resistant Gram-negative pathogens are a significant burden on the US healthcare system. This problem has been further compounded by the recent decline in the development of new antibiotics targeting Gram-negative organisms. US healthcare agencies have been working to limit the occurrence of HAIs by several means, including surveillance systems, prevention practices, antimicrobial stewardship policies and financial incentives. Furthermore, efforts have been made to resume the development of antibiotics in the USA, with the US FDA and US government both implementing acts to boost the number of antibiotics in the clinical pipeline. This review discusses the policies instigated by the US government, including healthcare agencies and the FDA, and describes new antibiotics in development against HAIs.
authors.affiliation: Department of Medicine, University of California, Irvine, 101 The City Drive South, Orange, CA 92868, USA.
authors.forename: Alpesh N
authors.initials: AN
authors.lastname: Amin
authors.affiliation: IPC Healthcare, 4605 Lankershim Blvd, Ste 617, North Hollywood, CA 91602, USA.
authors.forename: Dennis
authors.initials: D
authors.lastname: Deruelle
mesh_terms: D000900:Anti-Bacterial Agents / Q000302:isolation & purification* / Q000494:pharmacology*; D003428:Cross Infection / Q000453:epidemiology* / Q000517:prevention & control; D055808:Drug Discovery / Q000639:trends*; D016905:Gram-Negative Bacterial Infections / Q000188:drug therapy* / Q000453:epidemiology* / Q000517:prevention & control; D006291:Health Policy; D006801:Humans; D017053:Infection Control / Q000379:methods*; D014481:United States / Q000453:epidemiology
chemical_list: D000900:Anti-Bacterial Agents
keywords: Gram-negative pathogen; antibiotic; burden of disease; drug development; healthcare-associated infection